Determination of ZSTK474, a novel Pan PI3K inhibitor in mouse plasma by LC–MS/MS and its application to Pharmacokinetics

[1]  M. Moein,et al.  Bioanalytical method development and validation: Critical concepts and strategies. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  T. Sakaeda,et al.  Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  Tingjun Hou,et al.  Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. , 2015, Drug discovery today.

[4]  Mukesh C. Joshi,et al.  Potent phosphatidylinositol 3-kinase inhibitors and their biology. , 2014, Current drug discovery technologies.

[5]  Y. Seong,et al.  ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. , 2011, Oncology reports.

[6]  T. Yamori,et al.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system , 2010, Acta Pharmacologica Sinica.

[7]  Y. Takasaki,et al.  Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice , 2010, Arthritis research & therapy.

[8]  S. Dan,et al.  Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. , 2010, European journal of cancer.

[9]  Dexin Kong,et al.  ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms , 2007, Cancer science.

[10]  S. Hirono,et al.  Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. , 2006, Journal of the National Cancer Institute.

[11]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[12]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[13]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[14]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[15]  H. Sasahara,et al.  Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives. , 2000, Chemical & pharmaceutical bulletin.

[16]  T. Olah,et al.  The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. , 1999, Rapid communications in mass spectrometry : RCM.

[17]  Meihua Yang,et al.  Development and validation of an accurate and rapid LC-ESI-MS/MS method for the simultaneous quantification of aflatoxin B1, B2, G1 and G2 in lotus seeds , 2013 .